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Objectives: To report changes in practice brought about by COVID-19 and the im-
plementation of new guidelines for the management of tonsillitis and peritonsillar 
abscess (PTA), and to explore factors relating to unscheduled re-presentations for 
patients discharged from the emergency department (ED).
Design: Prospective multicentre national audit over 12 weeks from 6 April 2020.
Setting: UK secondary care ENT departments.
Participants: Adult patients with acute tonsillitis or PTA.
Main outcome measures: Re-presentation within 10 days for patients discharged 
from the ED.
Results: 83 centres submitted 765 tonsillitis and 416 PTA cases. 54.4% (n = 410) of 
tonsillitis and 45.3% (187/413) of PTAs were discharged from ED. 9.6% (39/408) of 
tonsillitis and 10.3% (19/184) of PTA discharges re-presented within 10 days, com-
pared to 9.7% (33/341) and 10.6% (24/224) for those admitted from ED. The subse-
quent admission rate of those initially discharged from ED was 4.7% for tonsillitis and 
3.3% for PTAs.
IV steroids and antibiotics increased the percentage of patients able to swallow from 
35.8% to 72.5% for tonsillitis (n = 270/754 and 441/608) and from 22.3% to 71.0% 
for PTA (n = 92/413 and 265/373).
77.2% of PTAs underwent drainage (n = 319/413), with no significant difference in 
re-presentations in those drained vs not-drained (10.6% vs 9.5%, n = 15/142 vs 4/42, 
P = .846).
Univariable logistic regression showed no significant predictors of re-presentation 
within 10 days.
Conclusions: Management of tonsillitis and PTA changed during the initial peak of the 
pandemic, shifting towards outpatient care. Some patients who may previously have 
been admitted to hospital may be safely discharged from the ED.
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1  | INTRODUC TION
The SARS-CoV-2 (COVID-19) pandemic led to necessary changes 
in the management of common ENT emergency presentations 
internationally, including tonsillitis and peritonsillar abscess 
(quinsy, PTA), two of the most common emergency presenta-
tions to ENT.1 It has been demonstrated that COVID-19 infection 
leads to high viral titres in the nasal and oral cavities,2 with virus 
transmission thought to be predominantly via aerosols or droplet 
formation.3,4 Aspects of the management of tonsillitis and PTA, 
including oral examination, PTA drainage and flexible nasendos-
copy, were considered to represent a potential route of transmis-
sion of COVID-19.5,6
In March 2020, new UK guidelines were issued for the manage-
ment of tonsillitis and PTA presenting to emergency departments 
(ED), in light of COVID-19.7 There were no accepted national guide-
lines in the UK for the management of tonsillitis or PTA prior to 
COVID-19 for comparison. The major shifts in practice proposed 
were as follows: the avoidance of oral examination; the routine 
discharge of patients who could swallow fluids and medications; 
the routine administration of intravenous (IV) medications to ef-
fect this; and the avoidance of PTA drainage if possible. This advice 
aimed to minimise the personnel involved in managing the acute 
presentation, reduce oral instrumentation, and to reduce admission 
rates, thus, preserving hospital bed capacity for the anticipated 
COVID-19 demand.
The implementation of these relatively untested guidelines re-
sulted in significant changes to established practices that had been 
shown to be safe over many years. This article aims to:
1. Report the findings of a 12-week prospective audit of acute 
tonsillitis and PTA care, conducted during the initial peak of 
COVID-19 in the UK.
2. Explore factors relating to unscheduled re-presentation to 
hospital in tonsillitis and PTA patients discharged from the 
ED.
2  | METHODS
The protocol for this study was published in advance at https://entin 
tegra te.co.uk. This manuscript has been prepared with reference to 
the STROBE checklist for cohort studies.8
2.1 | Ethical considerations
The Health Research Authority decision tool determined the study 
design to fall under the remit of audit, and so no ethical approval 
was required (available at: http://www.hra-decis ionto ols.org.uk/
resea rch/).
2.2 | Study design and setting
A national prospective audit of the hospital management of tonsillitis 
and PTA by UK secondary care ENT departments was conducted, 
in parallel to an audit of acute epistaxis emergency care.9 The 
audit was developed and run by INTEGRATE, the UK ENT Trainee 
Research Network. All UK ENT departments were invited to partici-
pate via advertisement, and registration with local audit and Clinical 
Governance Departments was required. Sites could open at any 
point during the prospective data collection period.
2.3 | Participants
Consecutive patients with tonsillitis and PTA, aged 18 years and 
older, and referred to ENT secondary care, were eligible for inclu-
sion, whether managed by telephone advice or face-to-face review.
2.4 | Data collection
Eligible cases were identified over a 12-week period, between 6 April 
2020 and 29 June 2020. Each case was followed-up for 10 days. A 
standardised electronic case report form was created using Excel 
software (Microsoft Corporation, Washington, USA) and made avail-
able online (Supplementary material), incorporating data validation 
to encourage valid data entry and completeness. Data were initially 
held offline at each centre, and patient identifiable data were re-
moved prior to submission to the project management team. Data 
were collected on: patient demographics; COVID-19 status; review-
ing clinicians; IV medications and their effect; discharge medica-
tions; examinations performed; and PTA drainage.
Key Points
1. Fewer patients presented to the emergency department 
(ED) with tonsillitis and peritonsillar abscess (PTA) dur-
ing the COVID-19 pandemic.
2. IV antibiotics and steroids given in the ED led to a two-
fold-threefold increase in the proportion of patients 
able to swallow, to over 70%.
3. Approximately half of tonsillitis and PTA patients were 
discharged from the ED, without an increase in later 
admission.
4. Nearly, a quarter of patients with suspected PTA had no 
drainage performed, and re-presentation rates were not 
higher in this group
5. There were no significant predictors of re-presentation 
in those discharged from ED.
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2.5 | Interim reports
The 12-week audit was divided into three 4-week periods. Two 
interim reports were produced (after periods 1 and 2) allowing for 
rapid feedback of management and preliminary outcomes to the 
UK ENT community. Both interim reports were disseminated elec-
tronically via ENTUK mailouts within 10 days of data submission and 
hosted online at https://entuk.org and https://entin tegra te.co.uk.
2.6 | Data analysis
The primary outcome was unscheduled re-presentation to hospital 
within 10 days for ED discharges. This intended to assess the safety 
of the lower rates of admission anticipated.
Univariable binary logistic regression analysis was used to iden-
tify significant determinants of the primary outcome measure. The 
level of significance was set at < 0.05 with Bonferroni corrections 
applied, where applicable. Analysis was performed using R statistical 
software (R Foundation, Vienna, Austria).
3  | RESULTS
3.1 | Centres
Data were submitted by 83/86 UK centres who registered to take 
part (72 in England, 5 in Scotland, 3 in Wales and 3 in Northern 
Ireland) covering a total of 905 weeks. 2/83 centres submitted data 
covering the first period only. The dates centres opened are shown 
in Figure 1, alongside the median rates of tonsillitis and PTA cases 
referred per centre per week.
3.2 | Submissions
1,181 cases met the prespecified eligibility criteria across the three 
periods (765 tonsillitis cases [276, 212 and 277 cases, respec-
tively] and 416 PTA cases [131, 129 and 156 cases, respectively]). 
Characteristics of both populations are shown in Tables 1 and 2. 
Data completeness was 99.2% (n = 592/597) of cases having data 
for the primary outcome.
3.3 | COVID-19
Figure 1 shows the number of patients with suspected or confirmed 
COVID-19, at the time of presentation and following testing, for the 
three audit periods, alongside the UK incidence of COVID-19.
3.4 | Acute management of ED patients
An oral examination was performed in 91.0% of tonsillitis patients 
and 91.7% of PTA patients (n = 678/745 and n = 376/410). Flexible 
nasendoscopy (FNE) was performed in 4.6% of tonsillitis patients 
and 9.5% of PTA patients (n = 34/745 and n = 39/410).
The rates of use of IV medications are shown in Tables 1 and 2. IV 
antibiotics were given in 79.6% of tonsillitis patients (n = 600/754) 
and 89.6% of PTA patients (n = 370/413). IV steroids were given in 
67.0% of tonsillitis patients (n = 505/754) and 73.6% of PTA patients 
(n = 304/413).
Suspected PTA underwent attempted drainage in 77.2% of cases 
(n = 319/413). Needle aspiration was used in 78.6% of these cases 
(n = 246/313) and produced pus in 54.4% (n = 134/246). Incision 
and drainage were used in 21.4% (n = 67/313) and produced pus in 
F I G U R E  1   Combination graphic to communicate trends in data over 12-week audit period: 1) The bar chart forming the background 
shows sequential opening of centres across the UK as the audit period progressed, 2) The box and whisker plots show the median, range and 
interquartile range of tonsillitis and quinsy patients presenting per centre per week for each of the three 4-week audit periods, 3) The scatter 
plot and error bars are COVID-19 swab rates (%) (diamonds) and positive swab rates (%) (crosses) with 95% confidence intervals, 4) The grey 
line chart is the 7-day rolling average of UK cases from 1 March to 31 July (available at: https://coron avirus.data.gov.uk/cases)
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82.1% (n = 55/67). Using either method, pus was obtained in 60.4% 
(n = 189/313). The reasons for no attempt at drainage were given as 
follows: 63.8% following guidelines (n = 60); 14.9% patient choice 
(n = 14); 10.5% not trained (n = 10); 8.5% trismus (n = 8); and 2.1% 
suspected COVID-19 (n = 2).
The administration of IV steroids and antibiotics increased the 
percentage of patients able to swallow from 35.8% to 72.5% for ton-
sillitis (n = 270/754 and 441/608) and from 22.3% to 71.0% for PTA 
(n = 92/413 and 265/373).
Telephone advice only was given by way of remote manage-
ment in 6.6% of tonsillitis cases (n = 50/759) and 3.6% of PTA cases 
(n = 15/413).
For tonsillitis cases, when seen face to face (n = 709), the majority 
of patients were reviewed by pre-specialty grade junior doctors (51.6%, 
n = 366) followed by specialty grade junior doctors (40.2%, n = 285), 
consultants (6.1%, n = 43), and nurse practitioners (2.1%, n = 15).
For PTA cases, when seen face to face (n = 398), the majority of 
patients were reviewed by pre-specialty grade junior doctors (48.2%, 
n = 192) followed by specialty grade junior doctors (41.2%, n = 164), 
consultants (7.8%, n = 31) and nurse practitioners (2.8%, n = 11).
3.5 | Admission to hospital from ED
Tables 1 and 2 show the discharge rates for tonsillitis and PTA pa-
tients reviewed by ENT after presenting to the ED. The overall dis-
charge rate was 54.4% for tonsillitis (n = 410/754) and 45.3% for PTA 
(n = 187/413). These data are also visualised in Figure 2.














Overall - 45.6 (344/754) 54.4 (410/754) 9.6 (39/408) -
Sex Female 45.3 (196/433) 54.7 (237/433) 10.6 (25/236) .406
Male 46.1 (148/321) 53.9 (173/321) 8.1 (14/172)












(18 to 68) vs (18 to 86)
(20 to 37) vs (21 to 34)
.791
Previous course of oral 
antibiotics
No 48.3 (184/381) 51.7 (197/381) 8.1 (16/197) .342
Yes 42.9 (160/373) 57.1 (213/373) 10.9 (23/211)
Examinations None 23.9 (16/67) 76.1 (51/67) 7.8 (4/51) .679
Yes (any) 47.8 (324/678) 52.2 (354/678) 9.7 (34/352)
Oral examination only 46.1 (297/644) 53.9 (347/644) 9.6 (33/345) .694
FNE only (0/0) (0/0) (0/0) -
Oral examination & FNE 79.4 (27/34) 20.6 (7/34) 14.3 (1/7) .575
Swallowing fluids/
medications prior to 
IV medications?
No 60.1 (291/484) 39.9 (193/484) 8.8 (17/193) .625
Yes 19.6 (53/270) 80.4 (217/270) 10.2 (22/215)
Swallowing fluids/
medications after IV 
medications?
No 97.6 (163/167) 2.4 (4/167) 0 (0/4) .991
Yes 38.8 (171/441) 61.2 (270/441) 7.8 (21/269)
Statim IV medications None 7.6 (11/144) 92.4 (133/144) 13.5 (18/133) .125
Yes (any) 54.6 (333/610) 45.4 (277/610) 7.6 (21/275)
IV antibiotics only 60.0 (63/105) 40.0 (42/105) 12.7 (30/237) .146
IV steroids only 20.0 (2/10) 80.0 (8/10) 11.1 (1/9) .986
IV antibiotics & steroids 54.1 (268/495) 45.9 (227/495) 7.1 (3/42) .126
Discharge medications None - (16) 12.5 (2/16) .652
Yes (any) - (374) 9.1 (34/372)
Oral antibiotics only - (350) 8.6 (30/348) .595
Oral steroids only - (2) 50.0 (1/2) .225
Oral antibiotics & 
steroids
- (22) 13.6 (3/22) .919
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Overall - 54.7 (226/413) 45.3 (187/413) 10.3 (19/184) -
Sex Female 58.5 (93/159) 41.5 (66/159) 6.2 (4/65) 0.178
Male 52.4 (133/254) 47.6 (121/254) 12.5 (15/120)
Age in years Cohort - - Re-presented vs no
Median 31 31 31 vs 32
(Range) (18 to 91) (18 to 85) (18 to 76) vs (18 to 85)
(Interquartile range) (25 to 42.75) (23 to 42.5) (25 to 51.5) vs (23 to 42) 0.407
Previous course of 
oral antibiotics
No 55.8 (121/217) 44.2 (96/217) 9.6 (9/94) 0.713
Yes 53.8 (105/195) 46.2 (90/195) 11.2 (10/89)
Examinations None 32.4 (11/34) 67.6 (23/34) 8.7 (2/23) 0.770
Yes (any) 56.9 (214/376) 43.1 (162/376) 10.7 (17/159)
Oral examination only 55.2 (186/337) 44.8 (151/337) 10.1 (15/148) 0.830
FNE only (0/0) (0/0) (0/0) -
Oral examination & 
FNE





No 63.2 (203/321) 36.8 (118/321) 11.2 (13/116) 0.609




No 89.8 (97/108) 10.2 (11/108) 20 (2/10) 0.439
Yes 47.9 (127/265) 52.1 (138/265) 11.6 (16/138)
Statim IV 
medications
None 7.5 (3/40) 92.5 (37/40) 2.9 (1/35) 0.140
Yes (any) 59.8 (223/373) 40.2 (150/373) 12.1 (18/149)
IV antibiotics only 66.7 (46/69) 33.3 (23/69) 4.3 (1/23) 0.762
IV steroids only 0 (0/3) 100 (3/3) 0 (0/3) 0.992
IV antibiotics & 
steroids
58.8 (177/301) 41.2 (124/301) 13.8 (17/123) 0.105
Discharge 
medications
None - (17) 12.5 (2/16) 0.785
Yes (any) - (167) 10.3 (17/165)
Oral antibiotics only - (155) 1.4 (2/140) 0.734
Oral steroids only - (0) (0/0) -
Oral antibiotics & 
steroids
- (12) 60.0 (15/25) 0.756
Drainage None 54.3 (51/94) 45.7 (43/94) 9.5 (4/42) 0.846
Yes (any) 54.9 (175/319) 45.1 (144/319) 10.6 (15/142)
I&D (any) 61.2 (41/67) 38.8 (26/67) 7.7 (2/26) 0.583
(Continues)














52.8 (130/246) 47.2 (116/246) 11.4 (13/114)
I&D, no pus 75.0 (9/12) 25.0 (3/12) 0 (0/3) 0.992
I&D, Pus 58.2 (32/55) 41.8 (23/55) 8.7 (2/23) 0.912
Needle aspiration, 
no pus
50.9 (57/112) 49.1 (55/112) 16.4 (9/55) 0.333
Needle aspiration, 
Pus
54.5 (73/134) 45.5 (61/134) 6.8 (4/59) 0.616
No pus (either 
method)
53.2 (66/124) 46.8 (58/124) 15.5 (9/58) 0.130
Pus (either method) 55.6 (105/189) 44.4 (84/189) 7.3 (6/82)
TA B L E  2   (Continued)
F I G U R E  2   Sankey chart visualising 
proportions of patients being admitted 
or discharged from the ED, with rates of 
subsequent re-presentation, stratified by 
A) IV steroid use for tonsillitis patients and 
B) drainage for PTA patients
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Discharge rates from ED before and after statim IV medica-
tions were as follows: tonsillitis 17.6% (n = 133/754) and 44.6% 
(n = 277/754); PTA 9.0% (n = 37/413) and 39.9% (150/376), 
respectively.
Length of stay data were available for all eligible patients admit-
ted to hospital. Patients staying ≥ 1 day, ≥2 days and ≥ 3 days were 
as follows: tonsillitis 61.9%, 38.1%, 14.2% (n = 213/344, 131/344 
and 49/344) and PTA 61.9%, 38.1%, 12.4% (n = 140/226, 86/226 
and 28/226).
3.6 | Planned follow-up for ED discharges
No follow-up was arranged in 71.7% of tonsillitis patients 
(n = 294/410) with 5.9% having face-to-face (n = 81/410) and 19.8% 
having telephone appointments scheduled (n = 81/410) (9 reported 
as “other”, 2 directly listed for tonsillectomy).
No follow-up was arranged in 50.3% of PTA patients (n = 94/187) 
with 8.6% having face-to-face (n = 16/187) and 38.5% having tele-
phone appointments scheduled (n = 72/187) (5 reported as “other”).
3.7 | Unscheduled re-presentation within 10 days
Re-presentation rates and outcomes from re-presentation are shown 
in Table 3. Further detail for ED discharges, by patient and manage-
ment factors, is shown in Tables 1 and 2. Figure 2 additionally shows 
re-presentation rates for tonsillitis patients being discharged from 
the ED receiving no IV steroid (10.2%, n = 10/98) and any IV ster-
oid (8.1%, n = 19/234), and tonsillitis patients admitted from the ED 
receiving no IV steroid (12.9%, n = 9/70) and any IV steroid (8.6%, 
n23/268).
Univariable logistic regression showed no significant predictors 
of re-presentation within 10 days (Tables 1 and 2). No deaths were 
recorded.
4  | DISCUSSION
COVID-19 led to significant disruption of well-established stand-
ards of care, but it is increasingly recognised that these changes may 
have unveiled positive developments in our management of certain 
conditions. This discussion focuses on lessons that can be learned 
from the collective national experience regarding the management 
of acute tonsillitis and PTA.
4.1 | COVID-19, tonsillitis and peritonsillar abscess
Sore throat and pharyngeal inflammation are recognised manifes-
tations of COVID-19,10 but a consistent association with acute ton-
sillitis has not been described. Acute tonsillitis may have a viral or 
bacterial aetiology, with acute bacterial tonsillitis often preceded 
by a viral infection.11 Coronaviruses are not one of the known viral 
pathogens frequently contributing to acute tonsillitis.12 The only 
comparable pre–COVID-19 presentation data comes from the UK 
Multicentre Audit of Quinsies (MAQ),13 where the mean number 
of cases of PTA alone was 3.9 per centre per month (325 cases 
over 2 months in 42 centres). This compares to 2.0 PTA cases 
per centre per month during the COVID-19 audit (416 cases over 
905 weeks of data across 83 centres). Given seasonal variation 
has limited effect,14 this apparent drop in presentations may be 
due to the reduced spread of common viral infection with COVID-
19 population measures, or a reduced willingness of patients to 
present to ED.15
4.2 | Changes to care during the 
COVID-19 pandemic
Acute management of tonsillitis and PTA in ED aims to reduce the 
proportion of patients that require admission. This practice has been 
advocated for several years,16,17 but COVID-19 provided further 
pressure to clinicians to only admit cases where essential.
During the audit, clinicians discharged just over half of tonsillitis 
patients, and just under half of those with PTA. This represents a 
significant shift in practice, with historically high levels of admission 
for tonsillitis presenting to ENT in the UK,16,18 and only 8% of PTA 
cases discharged from ED in 2014.13
The use of IV antibiotics and steroids in ED was common, with 
the majority of both tonsillitis and PTA patients receiving both. 
The effect of this treatment, and any concurrent analgesia, was 
dramatic. This management approach doubled the proportion 
of patients able to swallow fluids in the subgroup later deemed 










Admission rate after re-presentation 
as proportion of initial presentation 
management
% (n)
Tonsillitis admissions 9.7 (33/341) 24.2 (8/33) 66.7 (22/33) 6.5 (22/341)
Tonsillitis discharges 9.6 (39/408) 7.7 (3/38) 50.0 (19/38) 4.7 (19/408)
PTA admissions 10.7 (24/224) 70.8 (17/24) 83.3 (20/24) 8.9 (20/224)
PTA discharges 10.3 (19/184) 63.2 (12/19) 31.6 (6/19) 3.3 (6/184)
8  |     SMITH
suitable for discharge, with a large benefit also seen in those later 
admitted. This finding is in line with previous small studies that 
suggest IV steroids may reduce pain and trismus, facilitating ear-
lier oral intake.19-21
Another COVID-19-provoked shift in practice has been a 
move away from PTA drainage (cf MAQ), with the aim of reduc-
ing clinician exposure to aerosol and droplets. Nearly, a quarter 
of patients with suspected PTA had no drainage performed, and 
this did not appear to influence the decision to admit, nor did the 
presence or absence of pus on incision or aspiration. There was 
also no difference in 10-day re-presentation rates between those 
drained or managed conservatively. Inevitably milder or border-
line cases are more likely to have been managed conservatively in 
our dataset, however, a recent meta-analysis also demonstrated 
no difference in outcomes between patients initially treated with 
conservative or surgical interventions for PTA.22 This audit, com-
bined with ongoing emphasis on reducing clinician exposure to 
oral secretions, should promote further exploration of the role of 
conservative management of PTA, and outcomes associated with 
not draining.
Some aspects of management did not change with the introduc-
tion of COVID-19 guidelines. Avoidance of oral examination was 
recommended, yet 9 out of 10 patients still underwent an oral as-
sessment. Furthermore, once patients were admitted, the length of 
stay for both tonsillitis and PTA was between 1 and 2 days, the same 
as previously found.13
4.3 | Drivers of clinical decision-making
The ENTUK COVID-19 guidelines suggested the decision to admit 
should be primarily based on the patient's ability to swallow fluids 
and medication, with the initial triage focusing on airway concern 
and sepsis, similar to other published criteria.16-18,23 Unsurprisingly, 
the inability to swallow fluids and medications, especially after sta-
tim IV medications, led to admission in almost all cases. Physiological 
markers of sepsis were not recorded and so it is uncertain what role 
these played in the decision to admit.
4.4 | Outcomes from outpatient care
While discharging patients from ED can benefit patients and the hos-
pital, it must be balanced against the potential harm of deterioration 
or complications occurring within the community. 10-day re-presen-
tation rates were similar to or below previously reported data,16,17 
and considerably lower than the 30-day figure from MAQ.13 For 
both tonsillitis and PTA cohorts, the readmission rate was low, and 
higher in the group initially admitted from ED. Even in those patients 
re-presenting, many could continue to be managed as an outpatient 
after further review in ED. Enhanced management within ED and 
early discharge therefore appears safe.
4.5 | Implications for clinical practice
The practice adopted across the UK during the COVID-19 epi-
demic has reduced admissions, and to a lesser extent reduced 
possible clinician exposure to patient secretions. While the deci-
sion-making process currently adopted appears safe, it is difficult 
from the data to fully characterise the optimal pathway or criteria 
for admission.
Looking for possible improvements in current management, in 
this audit, the 101 patients not examined did not demonstrate a 
higher re-presentation rate. It could therefore be argued that the 
continued use of patient examination by an ENT clinician is not jus-
tified, given both the risk of COVID-19 transmission, and the exis-
tence of a common management pathway for tonsillitis and PTA, 
with unclear benefit of PTA drainage.
Given the observational nature of this study, it is not possible to 
determine exactly which tonsillitis and PTA patients can be routinely 
managed as outpatients, but the current guidance appears to pro-
vide a sound basis for triage, probably incorporating a review of the 
presence of physiological markers of sepsis. It has, however, been 
shown that a greater proportion of patients with these conditions 
can be safely managed at home than has traditionally been the case.
4.6 | Strengths and limitations of the study
This large prospective national study gives a comprehensive report 
of tonsillitis and PTA management and is uniquely placed to learn 
from the synchronous UK-wide changes in practice brought about 
by the initial peak of the COVID-19 pandemic. Despite disruption to 
routine care, extremely high levels of data completeness were seen.
To reduce the burden on data collection during a clinically chal-
lenging time, data were not collected on physiological parameters, lab-
oratory/imaging results and past medical history. The classification of 
patients as tonsillitis or PTA was solely based on clinician judgement, 
and some PTA treated conservatively may have not re-presented true 
abscesses. Re-presentations to community health care will have been 
missed, although these are unlikely to represent severe complications. 
Re-presentations beyond 10 days would also have been missed but 
this timeframe was chosen as a compromise between identifying the 
majority of instances of failed acute management and allowing rapid 
feedback to the ENT community via the interim reports. Finally, pa-
tient hospital-avoidance behaviour at the height of the pandemic likely 
raised the threshold for re-attending with milder complications.
5  | CONCLUSION
Presentations with tonsillitis and PTA during the initial peak of the 
COVID-19 pandemic were below previous rates. The management 
of these cases was notably different, with high rates of IV steroid 
use, avoidance of PTA drainage for some patients, and an overall 
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shift towards outpatient care. This national study highlights that 
many patients who may previously have been admitted to hospital 
following their acute assessment and management, may be safely 
discharged from the ED.
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